[Successful treatment of heavy-chain disease with etoposide]. 1997

K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
Division of Hematology, Tokyo Metropolitan Geriatric Hospital.

A 79-year-old man with marked hepatosplenomegaly and lymphadenopathy was admitted to the hospital. Analysis of serum protein resulted in the diagnosis of gamma-chain disease (total protein 6.2 g/dl, M-protein positive, IgG 4150 mg/dl, IgG-Fc fragment positive). Specimens obtained by lymph node biopsies showed infiltration of plasmacytoid cells, which were stained with anti-IgG but not with anti-kappa or anti-lambda antibodies. The patient was given combination chemotherapy, but without effect. Then a regimen of long-term administration of low-dose etoposide was begun, and resulted in remission of the lymphadenopathy, hepatosplenomegaly, and abnormal IgG.

UI MeSH Term Description Entries
D008297 Male Males
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D006362 Heavy Chain Disease A disorder of immunoglobulin synthesis in which large quantities of abnormal heavy chains are excreted in the urine. The amino acid sequences of the N-(amino-) terminal regions of these chains are normal, but they have a deletion extending from part of the variable domain through the first domain of the constant region, so that they cannot form cross-links to the light chains. The defect arises through faulty coupling of the variable (V) and constant (C) region genes. Franklin Disease,gamma-Chain Disease,mu-Chain Disease,Franklin's Disease,Franklins Disease,Heavy Chain Diseases,gamma Chain Disease,gamma-Chain Diseases,mu Chain Disease,mu-Chain Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
January 2012, Acta haematologica,
K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
February 2004, International journal of hematology,
K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
March 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
November 1990, Obstetrics and gynecology,
K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
April 2024, International journal of hematology,
K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
January 2009, American journal of therapeutics,
K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
March 2016, Pediatric blood & cancer,
K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
June 2002, Current treatment options in oncology,
K Ishikawa, and M Hirai, and H Tsutsumi, and T Kumakawa, and M Mori, and M Masami
May 1968, The New England journal of medicine,
Copied contents to your clipboard!